Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 16/20 | 0.50 |
| ▸ | MEN1 | O00255 | 11/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.50 |
| ▸ | MAPT | P10636 | 10/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 8/20 | 0.48 |
| ▸ | RAB9A | P51151 | 8/20 | 0.48 |
| ▸ | TP53 | P04637 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | USP2 | O75604 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179675 | 0.83 | GAA (0.48) | GAAMEN1KMT2AHSD17B10MAPT | |
| SCHEMBL27309318 | 0.82 | GAA (0.56) | GAAMEN1KMT2AHSD17B10MAPT | |
| SCHEMBL25003323 | 0.79 | MALT1 (0.51) | GAAMEN1KMT2AHSD17B10MAPT | |
| SCHEMBL5049960 | 0.78 | GAA (0.43) | GAAMEN1KMT2AHSD17B10MAPT | |
| SCHEMBL11573510 | 0.77 | GAA (0.50) | GAAMEN1KMT2AHSD17B10MAPT | |
| SCHEMBL30433645 | 0.77 | MEN1 (0.45) | GAAMEN1KMT2AHSD17B10HTT | |
| SCHEMBL9779443 | 0.76 | GAA (0.41) | GAAMEN1KMT2AHSD17B10MAPT | |
| SCHEMBL1258833 | 0.76 | GAA (0.55) | GAAMEN1KMT2AHSD17B10MAPT | |
| SCHEMBL9779474 | 0.76 | GAA (0.40) | GAAMEN1KMT2AHSD17B10MAPT | |
| SCHEMBL11564698 | 0.76 | LMNA (0.47) | MEN1KMT2AMAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108640919-B | Matrine derivative and sophoridine derivative containing aryl amidine or aminoquinoline structure and preparation method thereof | 广西大学 | 2020-09-08 | — | — | CN | claimed |
| CN-108640919-A | The matrine derivative and Sophoridine derivative and preparation method thereof of amidine containing aryl or aminoquinoline structure | 广西大学 | 2018-10-12 | — | — | CN | claimed |
| EP-4406957-B1 | ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | NOGRA PHARMA LTD (IE) | 2026-04-08 | — | — | EP | disclosed |
| US-12577256-B2 | Aryl receptor modulators and methods of making and using the same | NOGRA PHARMA LIMITED (IE) | 2026-03-17 | — | — | US | disclosed |
| WO-2025151311-A1 | NICOTINAMIDE DERIVATIVES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025119372-A2 | MRGPRX2 ANTAGONIST AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2025-06-12 | — | — | WO | disclosed |
| CN-120118069-A | MRGPRX2 antagonists and uses | 武汉人福创新药物研发中心有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20250163047-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2025-05-22 | — | — | US | disclosed |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250066384-A1 | ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | NOGRA PHARMA LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| US-12150995-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-1463733-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004058729-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | ALMIRALL PRODESFARMA SA (ES) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004004652-A2 | MITOTIC KINESIN BINDING SITE | MERCK & CO., INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003050064-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-1226119-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6479512-B1 | TO TREAT TYROSINE KINASE-DEPENDENT DISEASES AND CONDITIONS, SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, ETC. | MERCK & CO., INC. | 2002-11-12 | — | — | US | disclosed |
| EP-1226119-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO. INC. (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001028993-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO. INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| EP-0609371-B1 | THIENOPYRAZINE-2,3-DIONES USEFUL FOR TREATING CNS DISORDERS, AND THEIR PREPARATION. | NOVO NORDISK AS (DK) | 1996-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577256-B2 | Aryl receptor modulators and methods of making and using the same | AHR, IL23R, ARNT | GAA 2345/4885MEN1 4746/4885KMT2A 1428/4885 |
| US-20250066384-A1 | ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | AHR, IFNAR1, IL23R | GAA 880/4885MEN1 4801/4885KMT2A 2217/4885 |
| US-20250163047-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | NFATC1, GZMB, IFNG | GAA 1864/4885MEN1 3461/4885KMT2A 1047/4885 |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GAA 1234/4885MEN1 4055/4885KMT2A 445/4885 |
| US-12150995-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GAA 1234/4885MEN1 4055/4885KMT2A 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.